Stay updated with breaking news from Naim Shehadeh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investigators found that the adjusted mean change in A1C was –0.62% for dapagliflozin compared to 0.41% for a placebo in patients with type 2 diabetes.
Positive results from the T2NOW Phase III trial demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga compared with patients receiving...
Type-2 diabetes is surging among Israeli youths – 10-fold higher among Arabs compared to 3.5-times more among their Jewish counterparts